We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





New Biosensor Detects COVID-19 Virus in Air

By HospiMedica International staff writers
Posted on 25 Apr 2020
A team of researchers from Switzerland has succeeded in developing a novel sensor for detecting the new coronavirus that could be used to measure the concentration of the virus in the environment, such as in places where there are many people or in hospital ventilation systems.

The researchers from Empa (Zürich, Switzerland) and ETH Zurich (Zürich, Switzerland) usually work on measuring, analyzing and reducing airborne pollutants such as aerosols and artificially produced nanoparticles. More...
However, the COVID-19 challenge being faced by the whole world made the team shift its focus to developing a sensor that can quickly and reliably detect SARS-CoV-2 - the new coronavirus. Even before the COVID-19 began to spread, the team was researching sensors that could detect bacteria and viruses in the air and in early January, it came up with the idea of using this basis to further develop the sensor in such a way that it could reliably identify a specific virus was born. The sensor would not necessarily replace the established laboratory tests, but could be used as an alternative method for clinical diagnosis, and more prominently to measure the virus concentration in the air in real time, such as in busy places like train stations or hospitals.

As opposed to the molecular method called reverse transcription polymerase chain reaction, or RT-PCR for short, used in labs to detect viruses in respiratory infections, the researchers have developed an alternative test method in the form of an optical biosensor. The sensor combines two different effects to detect the virus safely and reliably: an optical and a thermal one. The sensor is based on tiny structures of gold, so-called gold nanoislands, on a glass substrate. Artificially produced DNA receptors that match specific RNA sequences of the SARS-CoV-2 are grafted onto the nanoislands. The receptors on the sensor are the complementary sequences to the virus' unique RNA sequences, which can reliably identify the virus.

To demonstrate how reliably the new sensor detects the current COVID-19 virus, the researchers tested it with a very closely related virus: SARS-CoV which broke out in 2003 and triggered the SARS pandemic. The validation was successful although a number of developmental steps are still needed to enable the sensor to measure the coronavirus concentration in the air.

“Tests showed that the sensor can clearly distinguish between the very similar RNA sequences of the two viruses,” said Jing Wang, one of the researchers. “This still needs development work. But once the sensor is ready, the principle could be applied to other viruses and help to detect and stop epidemics at an early stage.”

Related Links:
Empa
ETH Zurich



Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
New
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Gas Analyzer
GE SAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image Credit: 123RF

AI Platform Screens for Amyloid Cardiomyopathy Using ECG Images

Amyloid cardiomyopathy is a heart disease caused by deposits of misfolded proteins in the cardiac muscle. It is often missed until patients develop serious complications such as heart failure.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.